SCM
VIR icon

Superstring Capital Management’s Vir Biotechnology VIR Stock Holding History

Superstring Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.55M Buy
+730,548
New +$5.82M 4.68% 7
2025
Q4 		– Sell
-150,312
Closed -$858K – 62
2025
Q3 		$858K Buy
+150,312
New +$769K 0.85% 31

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Superstring Capital Management's VIR Position: Q1 2026 in Review

Superstring Capital Management opened a new position in Vir Biotechnology (VIR) in Q1 2026: 730,548 shares worth $6.55M. The stake represents 4.68% of the portfolio and ranks #7 among its holdings. This is a return to the name: Superstring Capital Management previously reported a position in VIR as recently as Q3 2025.

Superstring Capital Management first reported a position in VIR in Q3 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Superstring Capital Management held 730,548 shares of Vir Biotechnology worth $6.55M as of Q1 2026.
  • Vir Biotechnology was a new Superstring Capital Management position in Q1 2026.
  • Vir Biotechnology made up 4.68% of Superstring Capital Management's portfolio in Q1 2026, its #7 holding.
  • Superstring Capital Management first reported a position in Vir Biotechnology in Q3 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.